Breaking Finance News

A report released earlier today by Piper Jaffray about Alexion Pharmaceuticals Inc. (NDAQ:ALXN) raises the target price to $170.00

Yesterday Alexion Pharmaceuticals Inc. (NDAQ:ALXN) traded -2.26% lower at $136.39. ALXN’s 50-day average is $142.33 and its two hundred day average is $127.81. With the last stock price close up 6.31% relative to the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Volume of trade was up over the average, with 1,917,547 shares of ALXN changing hands over the typical 1,552,850

In a report released on 10/23/2017 Piper Jaffray increased the target price of Alexion Pharmaceuticals Inc. (NDAQ:ALXN) to $170.00 indicating a possible upside of 0.25%.

Previously on 09/15/2017, RBC Capital Markets reported on Alexion Pharmaceuticals Inc. (NDAQ:ALXN) increased the target price from $0.00 to $161.00. At the time, this indicated a possible upside of 0.10%.

Performance Chart

Alexion Pharmaceuticals Inc. (NDAQ:ALXN)

With a total market value of $0, Alexion Pharmaceuticals Inc. has price-earnings ratio of 58.92 with a one year low of $96.18 and a one year high of $149.34 .

A total of 18 analysts have released a report on Alexion Pharmaceuticals Inc.. 7 brokers rating the stock a strong buy, six equity analysts rating the company a buy, seven equity analysts rating the stock a hold, 0 firms rating the stock a underperform, and finally zero equity analysts rating the company a sell with a one year target of $187.61.

More About Alexion Pharmaceuticals Inc. (NDAQ:ALXN)

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.